相关实验视频

Updated: May 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在肺腺癌中对furmonertinib的异常反应,其中包含HER2外因子20插入突变:一个病例报告

Lingyun Lou¹, Junwei Tu¹, Zhuoyang Zhao²

¹Department of Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, China.

Frontiers in oncology

|March 16, 2026

概括

弗蒙尔提尼布在治疗HER2突变非小细胞肺癌 (NSCLC) 中表现有前途. 该案例研究强调了其作为这种具有挑战性的突变的患者潜在的口服治疗的有效性和耐受性.

科学领域:

在瘤学瘤学.
医学科学医学科学医学科学

背景情况:

管理HER2突变非小细胞肺癌 (NSCLC) 提出了重大的临床挑战.
除了抗体与药物结合剂之外,还有有限的有效和可获得的治疗选择.
作为EGFR氨酸激酶抑制剂 (TKI) 的furmonertinib已对EGFR外20插入表现出活性,但不对HER2突变NSCLC表现出活性.

研究的目的:

为了评估furmonertinib在患有HER2突变NSCLC的患者中的疗效.
报告关于furmonertinib对HER2外子20插入 (ex20ins) 的第一个临床证据.

主要方法:

一名65岁的男性患有T4N0M1肺腺癌,患有ERBB2 p.Y772_A775dup突变.
弗蒙尔提尼布用双重标准剂量 (160毫克/天) 进行.
在初始给药后和化学疗法失败后重新挑战后,监测治疗反应和不良事件.

主要成果:

患者经历了症状和放射性改善在furmonertinib管理的5天内.
化学疗法后的furmonertinib重新挑战和sintilimab失败也在5天内引起了反应.
在治疗期间没有报告≥3级不良事件.

结论:

弗蒙尔提尼布在NSCLC中表现出对HER2 ex20ins突变的临床活性.
结构同质性可能解释了TKI与HER2突变的结合.
弗蒙尔提尼布为HER2突变NSCLC提供了一个潜在的成本效益高的口服治疗替代方案,需要进一步调查.

关键词:

在HER2中,HER2是HER2.案例报告案例报告在 exon 20 中插入插件.费尔蒙尼蒂尼布 (furmonertinib) 的使用情况非小细胞肺癌的肺癌.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...